<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166520">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944098</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00002417</org_study_id>
    <nct_id>NCT01944098</nct_id>
  </id_info>
  <brief_title>Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients</brief_title>
  <official_title>Systemic Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients: A Randomized, Placebo-Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the feasibility and safety of administering continuous
      intraoperative lidocaine infusions in adult patients undergoing laparoscopic Roux en Y
      Gastric Bypass (RYGB). The secondary objective is to determine if lidocaine administration
      versus placebo (dextrose administration) (initiated at the time of anesthesia induction and
      continued until extubation) will reduce postoperative narcotic requirements.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>6 hours post-surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analysis of patient outcome will involve a series of visual analogue scale pain evaluations during mobilization, coughing, and resting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>12 hours post-surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analysis of patient outcome will involve a series of visual analogue scale pain evaluations during mobilization, coughing, and resting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>18 hours post-surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analysis of patient outcome will involve a series of visual analogue scale pain evaluations during mobilization, coughing, and resting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>24 hours post-surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analysis of patient outcome will involve a series of visual analogue scale pain evaluations during mobilization, coughing, and resting</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bariatric Surgical Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative continuous IV infusion of Lidocaine at 2mg/kg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative continuous placebo infusion of dextrose at 2mg/kg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients between the ages of 18-65 years old

          -  BMI ≥ 40 kg/m2, ≤ 60 kg/m2

          -  Undergoing a primary laparoscopic RYGB by Dr. Murr

          -  Agree to be followed 24 hours postoperatively

          -  Normal K+ and Mg++ serum levels

        Exclusion Criteria:

          -  BMI less than 40 kg/m2, &gt; 60 kg/m2

          -  Laparoscopic RYGB surgery performed by a surgeon other than Dr. Murr

          -  Allergy to lidocaine

          -  Allergy to hydromorphone or ketorolac

          -  Allergy to corn or amide anesthetics

          -  Use of (thioridizine)

          -  Pregnancy

          -  Abnormalities of ALT or AST

          -  Intra-operative diagnosis of cirrhosis or portal hypertension

          -  Intraoperative complications per surgeon

          -  Intraoperative extensive adhesions per surgeon

          -  Chronic pain syndrome and chronic use of narcotics

          -  Severe back pain secondary to degenerative joint disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Karlnoski, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Florida Gulf-to-Bay Anesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Karlnoski, PhD</last_name>
    <phone>813.844.4413</phone>
    <email>rkarlnoski@fgtba.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Karlnoski, PhD</last_name>
      <phone>813-844-4413</phone>
      <email>rkarlnoski@fgtba.com</email>
    </contact>
    <investigator>
      <last_name>Enrico Camporesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>August 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
